GEN-MKT-18-7897-A
Sep 13, 2017 | Blogs, Life Science Research, Metabolomics | 0 comments
Why is metabolomics important?Metabolomics is the large-scale study of metabolites in biofluids, tissue extracts, or organisms. Metabolites are small (<1000 Da), biologically active molecules such as glucose, cholesterol, creatinine, hormones, lipids, and more.
Metabolomics provides valuable insight into the underlying processes of cells, diseases and, in turn, human health. Metabolites are the ultimate effectors of the cellular machinery, and represent the penultimate step in the progression from the genome, to proteome, to metabolome, to the phenotype.
By studying the metabolome, researchers can measure the dynamics of the cell response to internal or external perturbations, to build a better understanding of the underlying biology from the cell level to the organism level across all species. Such information supports the identification of biomarkers and biological pathways that are active or dormant during states of disease or health.
Why do we need precision medicine?Currently, patients are treated universally according to their disease diagnosis. However, many widely used drugs are ineffective for at least half of patients with diseases such as arthritis, diabetes, asthma, and depression. With the help of biomarkers and companion diagnostics (diagnostic tests used as a companion to a therapeutic drug to determine its applicability to a specific patient), researchers can stratify patients into subsets according to their disease progression and other key factors. This allows better prediction of disease outcomes so that more appropriate treatment regimes can be developed for the different sub groups. In turn, stratified medicine can give rise to precision medicine, where treatment is tailored for each patient according to their medical history, results from other tests, their response to medication and other clinical features.
How can metabolomics enable precision medicine?Collecting comprehensive metabolomics data depends on the simultaneous identification and quantification of hundreds of compounds in every sample. This requires robust, powerful and high-throughput mass spectrometry technologies with a very wide dynamic range to accommodate the diverse set of metabolic components present in a typical sample. Mass spectrometry has been heavily employed in this area due to the sensitivity delivered against other available technologies. With the growing interest in precision medicine, biomedical researchers are becoming increasingly dependent on fast, robust and accurate mass spectrometry-based technologies for comprehensive data collection on an industrialized scale. Users will demand ever-high throughput and accuracy for the rapid and reliable identification and quantification of every compound in thousands of samples.
SolutionsSCIEX offers several market-leading mass spectrometry solutions for metabolomics researchers who are conducting targeted screening of known compounds or carrying out discovery research to globally study the metabolome.
For metabolomics researchers performing longitudinal studies of large cohorts, SWATH Acquisition offers the robust workflow required to accurately identify and quantify nearly every detectable relevant metabolite in the sample. SWATH allows data to enter a permanent digital archive that can be re-interrogated at any time in the future.
Recent advances in mass spec for metabolomics and precision medicine
Future DirectionsThere is increasing interest within the scientific community in applying multi-omics approaches, where data from genomic, metabolomic, phenotypic and other studies are brought together to better inform stratified medicine approaches, and ultimately enable precision medicine.
Want to learn more about metabolomics and precision medicine?
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network